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with chronic hepatitis B virus (HBV) infection who are at risk of
developing progressive liver disease based upon their serum
ALT and HBV DNA levels and/or liver histology [1,2]. The seven
approved medications for chronic HBV consistently lead to histo-
logical improvements in patients that suppress HBV replication
during short-term treatment [3]. In addition, the rate of develop-
ing clinical outcomes and decompensation can be signiﬁcantly
reduced by using prolonged lamivudine therapy in patients with
advanced but compensated ﬁbrosis compared to no treatment
[4]. However, the clinical and histological beneﬁt with the oral
nucleos(t)ide analogues is substantially reduced when drug-
resistant variants of HBV emerge [3,4]. As a result, the oral agents
that most effectively suppress HBV replication with the lowest
rate of drug resistance during prolonged use (entecavir, tenofo-
vir) have emerged as preferred ﬁrst line agents over the other
available drugs (lamivudine, adefovir, telbivudine) [1,2].
Practice guidelines also recommend prescribing an oral nucle-
os(t)ide analogue (but not the interferons) for patients with
decompensated HBV cirrhosis independent of the patients serum
ALT, HBV DNA level, and eAg status [1,2]. These latter recommen-
dations are largely based upon open-label studies of lamivudine
and adefovir in decompensated HBV patients wherein antiviral
therapy was associated with improved outcomes including a
delay or prevention in the need for liver transplantation (Table 1)
[5–8]. For example, a prospective study of 154 decompensated
HBV patients treated with lamivudine demonstrated improved
laboratory and clinical parameters with treatment compared to
baseline values. A biphasic survival pattern was also noted with
most deaths occurring within the ﬁrst 6 months of treatment;
patients with higher pretreatment bilirubin, creatinine, and
HBV DNA levels were at greatest risk for early death while early
suppression of HBV replication was not associated with more
favorable outcomes [6]. Adefovir treatment in 226 patients with
lamivudine refractory decompensated HBV also led to signiﬁcantJournal of Hepatology 20
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cellular carcinoma; MELD, model for end stage liver disease.improvements in their CTP and MELD scores at 1-year compared
to baseline [7,8]. However, 14% still died within the ﬁrst year and
at least 33% required liver transplantation for long-term survival.
Although antiviral drug resistance is substantially less common
with adefovir monotherapy compared to lamivudine, concerns
remain regarding the slow rate of suppressing HBV replication
with adefovir as well as the potential for dose-dependent nephro-
toxicity in decompensated HBV patients [9,10].
Entecavir suppresses HBV replication more rapidly and effec-
tively than lamivudine in patients with compensated chronic
HBV [11]. In addition, entecavir was a more potent and rapid sup-
pressor of HBV replication compared to adefovir in compensated
patients [12]. Furthermore, entecavir does not have any reported
nephrotoxicity and the resistance proﬁle at 5 years in treatment
naïve HBV patients has been excellent (i.e., 1%) [13]. Tenofovir
is also a signiﬁcantly more potent suppressor of HBV replication
than adefovir and no drug-resistant variants have been reported
with 3 years of continuous treatment in compensated patients
[14,15]. Expanded use of these two newer drugs has been sought
in difﬁcult to treat patient populations, including hemodialysis
patients and subjects with decompensated HBV cirrhosis. How-
ever, safety and efﬁcacy data are very sparse to non-existent in
these special patient populations and this is due to uncertainties
in drug dosing and difﬁculties in conducting adequately powered
prospective studies.
In this issue of the Journal, the effectiveness of entecavir (at a
dose of 0.5 mg per day) in a cohort of 70 consecutive Korean
patients with decompensated HBV is reported [16]. The virologi-
cal responses in the 55 decompensated HBV patients at 1 year are
also compared to 144 compensated patients treated with enteca-
vir from the same center. Of note, none of these patients had pre-
viously been treated with an oral nucleos(t)ide analogue nor
harbored drug-resistant variants of HBV. As expected, the mean
MELD (11.5 vs. 7) and CTP scores (8.1 vs. 5.3) were signiﬁcantly
higher in the decompensated patients but the mean pretreatment
HBV DNA levels (7.2 vs. 7.5 log10) and proportion of HBeAg + pa-
tients (49.1% vs. 62.5%) was similar. Overall, the 1-year trans-
plant-free survival rate was 87.1% in the decompensated
patients. As previously reported with lamivudine, the majority
of adverse outcomes occurred within the ﬁrst 6 months of treat-
ment and these nine patients had more severe liver failure at
entry compared to the others. However, the baseline HBV DNA10 vol. 52 j 147–149
Table 1
Oral nucleos(t)ide analogues in decompensated HBV cirrhosis.
Study (reference) Fontana [6] Schiff [8] Liaw [21] Schiff [23] Shima [16]
Patients treated 154 226 191 112 70
(100) (91) (45) (45) (22)
Drug(s) used LAM ADV ETV (1 mg) vs. ADV TDF TVD ETVc ETV (0.5 mg)



















Entry HBV DNA (log10) Median = 8.0 7.0 + 1.6 7.5 + 0.2 8.2 + 0.2 5.7 6.3 5.9 7.2 + 1.2
1-year efﬁcacy and safety data
% HBV DNA undetectable >80%b 50% 57% 20% 71% 88% 73% 89%
% ;CTPP 2 NR NR 35% 27% NR 49%
Mean MELD; NR 2.0 2.6 1.7 2.0 2.0 2.0 2.2
% 1-year patient survival 84% 86% 84% 83% 86% 93% 91% 87%
Safety issues Disease ﬂare with LAM-R Nephrotoxicityd Nephrotoxicityd Nephrotoxicityd 7% worsening
liver diseaseHBV 6% 17% 24% 9% 7% 5%
ADV, adefovir; CTP, Child–Turcotte–Pugh score; ETV, entecavir; LAM, lamivudine; MELD, model for end stage liver disease; NR, not reported; TDF, tenofovir; TVD,
tenofovir + emtricitabine.
a Efﬁcacy data reported on 55 patients who survived 1-year.
b bDNA assay with a lower limit of detection of 0.7  105 genomes/ml.
c ETV dose varied from 0.5 to 1.0 mg per day depending upon pretreatment LAM-R.
d Nephrotoxicity deﬁned as * creatinine of >0.5 mg/dl from baseline.
Editoriallevels and presence of HBeAg+ were similar in the non-survivors
compared to the survivors. Similarly, the early response to antivi-
ral therapy among those who died or underwent transplant was
similar to the survivors. Nearly 50% of the entecavir treated
patients had a clinically signiﬁcant decrease in their CTP score
of >2 points at 1-year. In addition, the rate of HBeAg loss in both
the decompensated and compensated patients was remarkably
high at 1 year (48% and 41%, respectively). Finally, the kinetics
of HBV DNA suppression were comparable in the decompensated
and compensated patients.
Shim et al. are to be congratulated for providing important
prospectively collected data on the utility of entecavir in a large
group of patients with decompensated HBV cirrhosis. They con-
vincingly show that entecavir at a dose of 0.5 mg per day is effec-
tive in treating naïve decompensated HBV patients with nearly
90% achieving undetectable HBV DNA at month 12. In addition,
suppression of HBV DNA was maintained during follow-up with
no instances of viral rebound or entecavir-resistant HBV identi-
ﬁed. However, the authors also note that not all decompensated
patients improved with entecavir therapy and ﬁve patients devel-
oped HCC during follow-up. Furthermore, twelve subjects (22%)
showed no change in their CTP score at 1-year; four subjects
actually ‘‘experienced aggravation” of their liver disease with
worsening CTP scores. Whether this ‘‘aggravation” was related
to entecavir treatment or progression of their underlying liver
disease is unclear.
All of the approved oral nucleos(t)ide analogues for HBV carry
a BLACK-BOX warning in their labeling regarding potential mito-
chondrial toxicity that can manifest itself as lactic acidosis,
myopathy, neuropathy, or even hepatotoxicity. Entecavir had
the lowest risk of causing mitochondrial DNA depletion in an
in vitro test system compared to the other oral antiviral agents
[17,18]. Nonetheless, a recent report from Germany showed that
5 of 16 hospitalized patients with decompensated HBV developed
symptomatic lactic acidosis after receiving entecavir for 4–
240 days [19]. Although lactic acidosis resolved in four patients
following entecavir discontinuation or dose reduction, one
patient with fulminant HBV died. Whether these adverse events
were due to direct mitochondrial toxicity or other causes in these
patients who all had MELD scores > 20 remains unclear. It is148 Journal of Hepatology 201important to remember that mitochondrial toxicity can present
as late as 1 year after initiating oral nucleos(t)ide analogue ther-
apy and that concomitant drugs, medical co-morbidities, and
other host factors may alter drug pharmacokinetics in various tis-
sues [18,20]. Unfortunately, Shim et al. do not report upon ente-
cavir dose adjustments during treatment nor serial renal,
metabolic, or safety labs in their patients.
Preliminary reports from two other ongoing, multi-center
studies also suggest that entecavir may be of beneﬁt in selected
patients with decompensated HBV (Table 1). In the ﬁrst study,
195 patients with decompensated HBV were randomized to ent-
ecavir (1.0 mg per day) or adefovir (10 mg per day) [21]. In con-
trast to the Shim study, 34% of patients had lamivudine-resistant
HBV. Interim results at week 48 demonstrate a signiﬁcantly
greater reduction in HBV DNA and serum ALT levels in the ente-
cavir treated patients compared to the adefovir treated patients.
In addition, 1-year mortality rates were similar in both treatment
arms. These preliminary data conﬁrm the superior antiviral efﬁ-
cacy of entecavir compared to adefovir in decompensated HBV
patients. However, continued follow-up is needed since the rate
of entecavir-resistant HBV can substantially increase over time
in patients with lamivudine-resistant HBV and lead to potentially
severe disease ﬂares [13,22].
A second ongoing, multi-center study set out to compare the
safety and efﬁcacy of tenofovir vs. tenofovir + emtricitabine vs.
entecavir in 112 decompensated HBV patients [23]. In this study,
the median pretreatment MELD and CTP scores of 10.5 and 7,
respectively, were substantially lower than those reported in
the other studies (Table 1). The frequency of undetectable HBV
DNA at weeks 12, 24, and 48 was comparable in the three treat-
ment groups. However, amongst the subjects with lamivudine-
resistant HBV, 71% of the 18 patients in the tenofovir containing
arms had undetectable HBV DNA at week 48 compared to 33% in
the three entecavir treated patients. Improvements in CTP and
MELD scores at week 48 were comparable between the three
treatment arms but the rate of HBeAg seroconversion was 0% in
the entecavir arm compared to 21% and 13% in the tenofovir
and tenofovir/emtricitabine arms, respectively. Rates of nephro-
toxicity, treatment ‘‘tolerability” and patient mortality were sim-
ilar in the three treatment arms through week 48. Clearly,0 vol. 52 j 147–149
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continued follow-up of these patients is needed to determine
which of the newer antiviral agents can offer the best risk–beneﬁt
ratio in this challenging patient population. Although a tenofovir
based regimen may be preferred in decompensated patients with
lamivudine-resistant HBV, there are growing concerns regarding
the long-term safety of tenofovir in some HBV patients including
nephrotoxicity and metabolic bone disease [24,25]. Furthermore,
since patients with decompensated cirrhosis frequently are mal-
nourished and may have low vitamin D levels, prospective stud-
ies of bone density and metabolic parameters during prolonged
tenofovir treatment are warranted as well as potential calcium
and vitamin D supplementation [26].
In summary, the study of Shim et al. and others (Table 1) are
bright stars in the horizon for the management of decompensated
HBV cirrhosis. The aggregate efﬁcacy and safety data now sup-
port the use of entecavir as a ﬁrst line treatment option for nucle-
os(t)ide naïve patients with decompensated HBV cirrhosis.
However, continued follow-up from these ongoing studies
including long-term efﬁcacy, safety, and resistance data are
needed. Further studies are also needed to identify the optimal
agent(s) for patients with decompensated lamivudine-resistant
HBV cirrhosis. In the meanwhile, decompensated HBV patients
receiving oral nucleos(t)ide analogues must undergo frequent
clinical and laboratory assessment to insure medication compli-
ance and surveillance for virological and clinical response as well
as drug side effects, drug resistance, and HCC. Finally, the data of
Shim et al. conﬁrm the importance of early liver transplant eval-
uation in decompensated HBV patients with high MELD scores at
presentation due to our inability to reliably identify those
patients with a poor short-term prognosis.
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